SEOUL, South Korea, Oct. 15 /PRNewswire/ -- Dong-A PharmTech Co. Ltd announced today the signing of a five-year US$50 Million contract with Otechestvennye Lekarstva OJSC, to market in Russia Dong-A's erectile dysfunction drug which is currently sold in Korea under the brand name of Zydena.
Under the terms of the agreement, Otechestvennye Lekarstva OJSC, one of the largest Russian pharmaceutical firms, will pay both upfront fees and running royalty on sales for the life of the contract. This deal represents the second significant licensing deal for Dong-A, surpassing the contract signed last October with SCP Corp. (Saudi Arabia) for marketing in Gulf Cooperation Council territories
On the strength of Zydena's excellent efficacy and safety profile, Otechestvennye Lekarstva OJSC will make a significant investment in marketing and promoting to Russian physicians. Zydena is distinguished by its long duration of action and low incidence of unfavorable side effects such as vision disturbances and muscle pain. Zydena expects to achieve a market in excess of 20% in Korea in 2007, its second year of sale.
Mr. Dong Hyun Park, president of Dong-A PharmTech stated that "We are extremely pleased to have Otechestvennye as our partner in Russia. The deal with Otechestvennye Lekarstva OJSC positions Zydena for solid sales in the rapidly evolving pharmaceutical market in Eastern Europe and furthers our strategy for marketing Zydena in numerous key countries in Asia, and Latin & South American in advance of our entry into North America and the European Union."
Zydena has a strong intellectual property position with more patents in more than 30 countries. Dong-A PharmTech successfully completed its phase 2 clinical programs in the USA for erectile dysfunction and will proceed to completing all clinical studies required for filing a New Drug Application in the USA and Europe.
Dong-A PharmTech expects to increase global marketability of Zydena by
|SOURCE Dong-A PharmTech|
Copyright©2007 PR Newswire.
All rights reserved